Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.



from The Medical News http://www.news-medical.net/news/20141229/Palatin-begins-bremelanotide-phase-3-study-for-treatment-of-female-sexual-dysfunction.aspx